[3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienyl]triphenylphosphonium sulphate

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

no data

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Basic data are given, pre-GLP study.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1975

Report date:

1975

Materials and methods

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Principles of method if other than guideline:

BASF Test (internal method). In principle, the methods described in OECD TG 401 were used.

GLP compliance:

no

Remarks:

pre-GLP study

Test type:

standard acute method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

[3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienyl]triphenylphosphonium sulphate

EC Number:

212-028-2

EC Name:

[3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienyl]triphenylphosphonium sulphate

Cas Number:

751-83-7

Molecular formula:

C33H38P.HO4S

IUPAC Name:

mono[3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienyl]triphenylphosphonium hydrogensulphate

Details on test material:

- Name of test material (as cited in study report): C15-Salz, i.e. beta-ionylidene ethyl-triphenylphosphonium hydrogensulphate, solid
- Analytical purity: no data
No further data

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

no further data

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

olive oil

Details on oral exposure:

VEHICLE
- Concentration in vehicle: 0.02 - 35 % suspension in olive oil

Doses:

1000, 1470, 2150, 4640, 6810 mg/kg bw

No. of animals per sex per dose:

groups of 5 rats per sex

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Body weight was determined before the start of the study for determination of dose. Animals were observed approximately 1-3 hours after dosing and then daily over a period of 7-14 days
- Necropsy of survivors performed: yes. At necropsy, all rats were examined for gross pathological changes.
- Other examinations performed: clinical signs, body weight, gross pathology

Statistics:

no data

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

1 735 mg/kg bw

95% CL:

1 248 - 2 412

Mortality:

Mortality was observed at all dose levels, late deaths were noted at lower doses. For details, see table below.

Clinical signs:

other: Clinical signs of toxicity comprised prone position, apathy, diarrhea, exsiccosis, spastic gait, marked emaciation, and reddish encrustations at the snout and nose.

Gross pathology:

Pathology revealed acute dilatation of the heart, congestive hyperemia, dilatation of the stomach and liquid content of the stomach, eschar (from caustic), intraabdominal adhesions, and diarrhetic intestinal content

Any other information on results incl. tables

Table: mortality rates

Dose [mg/kg bw]	Mortality after
	1 h	48 h	14 d
1000	0/10	0/10	2/10
1470	0/10	3/10	4/10
2150	0/10	8/10	10/10
4640	0/10	10/10	10/10
6810	0/10	10/10	10/10

Applicant's summary and conclusion

Interpretation of results:

Category 4 based on GHS criteria

Remarks:

Migrated information

Conclusions:

According to the authors, the test substance was moderately toxic after oral ingestion.